tafasitamab-cxix

{
  "id": "MLC-T-ONC-016961",
  "term": "tafasitamab-cxix",
  "field": "Oncology and biomedicine",
  "definition": "An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Tafasitamab-cxix targets and binds to CD19, thereby depleting and eliminating CD19-expressing B cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.",
  "synonyms": [
    "tafasitamab",
    "immunoglobulin, anti-(human Cd19 antigen) (human-mus musculus monoclonal MOR00208 heavy chain), disulfide with human-mus musculus monoclonal MOR00208 .kappa.-chain, dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tafasitamab-cxix/"
}